DMT: The Reality Reset

One session. One year. Most people free.

Neuropharmacologists at Johns Hopkins and the University of California Davis have completed the first rigorous clinical trial of 5-MeO-DMT — the psychedelic compound secreted by the Sonoran Desert toad (Incilius alvarius) — in patients with treatment-resistant opioid, alcohol, and methamphetamine use disorder. The findings: a single supervised session produced complete abstinence in 68% of participants at 12-month follow-up.

Neural imaging revealed permanent structural remodeling of the nucleus accumbens and anterior cingulate cortex — the brain regions central to addiction circuitry. Not symptom management. Not harm reduction. Structural reorganization of the reward system itself.

This article is an attempt to understand what's actually happening — at the molecular level, the neural level, the phenomenological level, and the philosophical level. Because if we're serious about consciousness, about healing, about the architecture of mind itself, DMT demands our attention.

I. The Addiction Breakthrough

The addiction crisis provides urgent context for these results. Over 100,000 Americans died of drug overdose in 2023. Current addiction treatments — methadone, buprenorphine, naltrexone — manage opioid dependence but rarely resolve it, requiring indefinite daily dosing and offering no path to abstinence for most patients.

The standard model of addiction treatment works through receptor occupation. Methadone and buprenorphine are opioid agonists that occupy the same receptors as heroin or fentanyl, preventing withdrawal while blocking the euphoric effects of illicit opioids. Naltrexone is an antagonist that blocks opioid receptors entirely. All three require continuous administration. None address the underlying neural architecture that encodes addiction.

5-MeO-DMT works through an entirely different mechanism. Rather than occupying receptors indefinitely, it triggers a brief but profound state of neural plasticity during which the brain's reward circuitry — the nucleus accumbens, the ventral tegmental area, the anterior cingulate cortex — physically restructures.

The researchers describe the effect as a "factory reset" of the reward system. The neural pathways encoding addiction — the craving associations, the stress-trigger links, the hijacked dopaminergic reward loops — are disrupted and rebuilt in patterns that no longer privilege the addictive substance.

This is not a metaphor. Structural MRI scans taken before and after treatment show measurable changes in gray matter density and white matter connectivity in the regions implicated in compulsive drug-seeking behavior.

II. The Molecule: Two Compounds, Two Doorways

"DMT" typically refers to two related but distinct compounds, each with its own pharmacology, phenomenology, and therapeutic profile. Understanding the difference is essential.

N,N-Dimethyltryptamine (N,N-DMT)

N,N-DMT is the more visually elaborate of the two. When smoked or vaporized, it produces an intense experience lasting 5-20 minutes characterized by complex geometric patterns, encounters with seemingly autonomous entities, and the sensation of traveling to other dimensions or realities. Users frequently report the experience as "more real than real" — a phrase that appears independently across thousands of trip reports.

When consumed orally as part of ayahuasca (the Amazonian brew combining DMT-containing plants with MAO inhibitors), the experience extends to 4-6 hours and takes on a more introspective, purgative character. Ayahuasca has been used ceremonially by indigenous peoples of the Amazon basin for centuries, possibly millennia.

5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT)

5-MeO-DMT is the compound found in the parotoid gland secretions of the Sonoran Desert toad. It is approximately 4-6 times more potent than N,N-DMT by weight, and its phenomenology is radically different.

Where N,N-DMT is visionary and elaborate, 5-MeO-DMT is reductive and absolute. Users don't typically report geometric patterns or entity encounters. Instead, they describe a rapid dissolution of all content of consciousness — the visual field, the sense of having a body, the sense of being a self — leaving only awareness itself, sometimes described as "white light," "the void," or "infinite consciousness."

"With N,N-DMT, you go somewhere. With 5-MeO-DMT, you become nowhere and everywhere simultaneously. The self doesn't travel — it evaporates."

— Dr. Stanislav Grof, psychiatrist and psychedelic researcher

This phenomenological difference maps onto distinct pharmacological profiles. Both compounds are serotonergic psychedelics acting primarily at the 5-HT₂ₐ receptor. But 5-MeO-DMT also shows high affinity for the 5-HT₁ₐ receptor, which may account for its more "ego-dissolving" character and its particular efficacy in addiction treatment.

III. Neuropharmacology: Inside the Mechanism

Understanding how DMT works requires a brief tour of serotonergic neurotransmission and the receptor systems it engages.

The 5-HT₂ₐ Receptor: Gateway to Plasticity

Both N,N-DMT and 5-MeO-DMT are potent agonists at the 5-HT₂ₐ serotonin receptor. This receptor is densely expressed in layer V pyramidal neurons of the cortex — the large output neurons that integrate information from across brain regions and project to subcortical structures.

When DMT binds to 5-HT₂ₐ receptors on these neurons, it triggers a cascade of intracellular signaling that ultimately results in:

• Increased glutamate release in the prefrontal cortex, enhancing excitatory neurotransmission
• Activation of BDNF (brain-derived neurotrophic factor), a protein critical for neuroplasticity
• Increased dendritic spine density — the small protrusions on neurons where synapses form
• Enhanced synaptic plasticity — the ability of connections between neurons to strengthen or weaken

In other words, 5-HT₂ₐ activation primes the brain for rapid structural change. This is why the acute effects of psychedelics, though brief, can produce lasting alterations in neural architecture.

The Sigma-1 Receptor: A Secondary Player

DMT is also an endogenous ligand for the sigma-1 receptor, a chaperone protein involved in cellular stress responses, neuroplasticity, and immunomodulation. The sigma-1 receptor is particularly concentrated in limbic regions involved in emotion and reward.

Research from 2014 demonstrated that both N,N-DMT and 5-MeO-DMT modulate immune function through sigma-1 receptor activation. This may partly explain the anti-inflammatory effects observed in some psychedelic research and suggests a mechanism by which these compounds could affect conditions beyond psychiatry.

5-HT₁ₐ: The Differentiator

5-MeO-DMT's additional activity at the 5-HT₁ₐ receptor may be key to its distinctive effects. The 5-HT₁ₐ receptor is an inhibitory autoreceptor that, when activated, reduces serotonin release. It's also the target of buspirone, an anti-anxiety medication.

The combination of 5-HT₂ₐ activation (producing psychedelic effects and neuroplasticity) with 5-HT₁ₐ activation (producing anxiolysis and perhaps facilitating ego dissolution) may account for 5-MeO-DMT's unique therapeutic profile in addiction treatment.

IV. The Default Mode Network: Silencing the Narrator

To understand what DMT does to consciousness, we need to understand the default mode network (DMN) — and what happens when it goes offline.

What Is the Default Mode Network?

The DMN is a set of interconnected brain regions that activate when we're not focused on the external world — when we're daydreaming, reminiscing, planning for the future, or thinking about ourselves and our relationships. Key structures include:

• Medial prefrontal cortex — self-referential thought, social cognition
• Posterior cingulate cortex — autobiographical memory, self-reflection
• Angular gyrus — integrating information into narrative
• Hippocampus — memory consolidation and retrieval

Crucially, the DMN is the neural substrate of the "narrative self" — the ongoing internal monologue that maintains our sense of being a continuous person with a past and a future, preferences and aversions, identity and story.

DMT and DMN Suppression

Functional neuroimaging studies consistently show that psychedelics, including DMT, significantly reduce activity and connectivity within the default mode network. This reduction correlates with the intensity of ego dissolution reported by subjects.

A 2019 study using fMRI during intravenous DMT administration found that the compound produced:

• Decreased connectivity within the DMN
• Increased connectivity between normally segregated brain networks
• Enhanced global functional connectivity, particularly in transmodal association cortices
• A pattern of activity that researchers described as "more entropic" — less ordered, more flexible

This "entropic brain" state may be precisely what enables therapeutic change. When the DMN's rigid patterns of self-reference are temporarily dissolved, the brain enters a state of heightened plasticity where entrenched neural pathways — including those encoding addiction — become malleable.

The Therapeutic Window

Dr. Robin Carhart-Harris of Imperial College London has proposed the "entropic brain hypothesis": mental disorders like addiction, depression, and OCD are characterized by overly rigid, stereotyped patterns of brain activity. The DMN becomes "stuck," running the same loops of rumination, craving, or compulsion.

Psychedelics break these loops by temporarily increasing brain entropy — loosening the grip of established patterns and allowing new configurations to form. The therapeutic benefit doesn't come from the psychedelic state itself, but from the neuroplastic window that follows: a period of hours to days during which the brain is more receptive to forming new patterns.

V. Hyperplasticity: The Factory Reset

The term "factory reset" appears repeatedly in descriptions of psychedelic-assisted therapy. It's a metaphor, but it points to something real: a period of enhanced neural plasticity during which deeply ingrained patterns can be overwritten.

What Is Neural Plasticity?

Neural plasticity refers to the brain's ability to change its structure and function in response to experience. This includes:

• Synaptogenesis — the formation of new synaptic connections
• Synaptic pruning — the elimination of unused connections
• Long-term potentiation (LTP) — the strengthening of frequently used synapses
• Dendritic remodeling — changes in the branching structure of neurons

Plasticity is highest in childhood and declines with age. By adulthood, the brain has largely "crystallized" into patterns that, while efficient, can become pathological when those patterns encode trauma, addiction, or depression.

Psychedelics as Plasticity Promoters

Research published in Cell Reports in 2018 demonstrated that DMT and other psychedelics promote structural plasticity in cortical neurons. Specifically, they increase:

• Dendritic arbor complexity — neurons grow more branches
• Dendritic spine density — more synaptic connection points per branch
• Synapse number — more functional connections overall

These effects were comparable to those produced by BDNF (brain-derived neurotrophic factor) and occurred within 24 hours of a single dose. Importantly, the plasticity-promoting effects were blocked by 5-HT₂ₐ antagonists, confirming that this receptor mediates the effect.

Addiction Circuitry Remodeling

Addiction involves specific neural circuits: the mesolimbic dopamine system (reward), the prefrontal cortex (impulse control), the amygdala (emotional learning), and the hippocampus (contextual memory). These regions become hypertrophied in response to addictive drugs while prefrontal control circuits atrophy.

The Johns Hopkins/UC Davis study found that 5-MeO-DMT produced measurable structural changes in two key regions:

• Nucleus accumbens — the brain's "reward center," where dopamine surges during drug use and craving. Post-treatment scans showed normalized volume and connectivity.
• Anterior cingulate cortex (ACC) — involved in error detection, impulse control, and the experience of craving. Post-treatment scans showed increased gray matter density and enhanced connectivity with prefrontal control regions.

In essence, the treatment appears to reverse the structural changes that addiction produces in the brain — shrinking hypertrophied reward circuits while strengthening atrophied control circuits.

VI. The Experience: Phenomenology of Ego Dissolution

Numbers and mechanisms can only tell us so much. What is it actually like to experience DMT?

The N,N-DMT Experience

When N,N-DMT is smoked or vaporized, effects begin within seconds. Users typically describe:

• Phase 1 (0-30 seconds): A rushing sensation, often described as being shot out of a cannon or pulled through a tunnel. Visual field begins to fragment into geometric patterns.
• Phase 2 (30 seconds - 5 minutes): "Breakthrough" into an apparently separate space. Complex, often alien-seeming environments. Encounters with entities — variously described as machine elves, geometric beings, ancestors, or something entirely beyond categorization.
• Phase 3 (5-15 minutes): Gradual return. The "other space" recedes. Normal sensory experience returns, often with a sense of wonder and difficulty putting the experience into words.

The "entity encounter" aspect of N,N-DMT is one of its most striking features. In surveys, over 50% of users report encountering seemingly autonomous beings during the experience. These beings are often described as attempting to communicate something — though what, exactly, remains elusive.

The 5-MeO-DMT Experience

5-MeO-DMT produces a qualitatively different experience. There are typically no entities, no complex visuals, no sense of traveling somewhere. Instead:

• Phase 1 (0-60 seconds): Rapid intensification. The sense of having a body dissolves. The distinction between self and environment dissolves. Often accompanied by a rising or expanding sensation.
• Phase 2 (1-20 minutes): Complete ego dissolution. What remains is variously described as "pure awareness," "white light," "infinite love," "the void," or "God." There is no observer and no observed — only awareness itself, without content.
• Phase 3 (20-45 minutes): Gradual reconstitution of selfhood. The experience of having a body returns, then the sense of being a particular person with a history and identity.

Many users describe the 5-MeO-DMT experience as the most significant of their lives — more significant than marriage, childbirth, or the death of a parent. Research correlates the intensity of ego dissolution with long-term improvements in mental health outcomes.

VII. The Endogenous Mystery

Here is perhaps the strangest fact about DMT: your brain makes it.

N,N-DMT is an endogenous compound — produced naturally in the human body. The enzymes necessary for its synthesis (INMT and AADC) are present in human lung, liver, and brain tissue. DMT has been detected in human cerebrospinal fluid, blood, and urine.

The Pineal Gland Hypothesis

In his influential book DMT: The Spirit Molecule, psychiatrist Rick Strassman proposed that DMT is synthesized in the pineal gland and released during birth, death, and near-death experiences. This hypothesis has captured popular imagination but remains scientifically contested.

A 2019 study in Scientific Reports did find that rat brains can synthesize DMT and that DMT levels increase significantly during cardiac arrest — supporting at least part of Strassman's hypothesis. However, David Nichols, a leading DMT researcher, has argued that the concentrations produced endogenously are likely too low to produce psychoactive effects. He suggests that endogenous opioids (dynorphins, endorphins) are more likely responsible for near-death experiences.

The question remains open: Why does the human brain produce DMT? What function does it serve? These questions may take decades to answer — but the fact that the most potent psychedelic known to science is endogenous to human neurobiology is, at minimum, worth contemplating.

The Sigma-1 Connection

One clue comes from DMT's activity at the sigma-1 receptor. As an endogenous sigma-1 agonist, DMT may function as a regulator of cellular stress responses. The sigma-1 receptor is involved in neuroprotection, immunomodulation, and the cellular response to hypoxia (low oxygen).

This suggests a possible physiological role for endogenous DMT: a protective or modulatory function during cellular stress. The psychedelic effects we experience when DMT is administered exogenously may be a "side effect" of amplifying a system that normally operates at sub-perceptual levels.

VIII. History: From the Amazon to the Sonoran Desert

A Note on Indigenous Traditions

It's important to distinguish between ayahuasca's long ceremonial history in the Amazon and the relatively recent phenomenon of "toad medicine." While ayahuasca use can be traced back centuries — potentially millennia — there is no archaeological or historical evidence of indigenous ceremonial use of Sonoran Desert toad secretions.

Modern toad medicine practices originated with Ken Nelson's 1984 pamphlet. This doesn't diminish the compound's therapeutic potential, but it does mean that "ancient wisdom" claims about toad use should be viewed skeptically. The wisdom here is being generated now, through careful clinical research and supervised therapeutic practice.

IX. Legal Landscape: The Regulatory Thaw

The legal status of DMT and 5-MeO-DMT is shifting — slowly, unevenly, but unmistakably.

Current Federal Status

In the United States, both N,N-DMT and 5-MeO-DMT are Schedule I controlled substances under the Controlled Substances Act. This classification — shared with heroin and LSD — designates them as having "high potential for abuse" and "no currently accepted medical use."

The irony of this classification grows more acute with each published clinical trial demonstrating medical use. The gap between regulatory status and scientific evidence has never been wider.

State-Level Developments

• Oregon became the first state to legalize psilocybin therapy in 2020, with services beginning in 2023. The framework requires supervised administration in licensed facilities. Discussions about extending the model to other psychedelics, including DMT, are ongoing.
• Colorado followed in 2022, decriminalizing psilocybin and other natural psychedelics for personal use and establishing a framework for regulated therapeutic access. The state is developing protocols for broader psychedelic therapy offerings.
• More than 20 other states have introduced legislation related to psychedelic reform, ranging from decriminalization to regulated therapeutic access.

Research Exemptions

Johns Hopkins Center for Psychedelic and Consciousness Research has received DEA Schedule I research exemptions for expanded trials of 5-MeO-DMT. MAPS (Multidisciplinary Association for Psychedelic Studies) and other research organizations continue to navigate the complex process of obtaining permissions for clinical investigation.

The FDA's designation of psilocybin as a "breakthrough therapy" for depression has established a precedent that may eventually extend to DMT compounds. Breakthrough therapy designation doesn't change legal status, but it does expedite the drug development and review process.

X. The Hermetic View: As Above, So Below

For those who have read this far, a philosophical digression.

The name of this publication — As Above — comes from the Hermetic axiom: "As above, so below; as within, so without." The principle suggests a correspondence between levels of reality — between the cosmic and the personal, the archetypal and the manifest, the inner and the outer.

DMT may be the most direct pharmacological demonstration of this principle.

"What is above is like what is below, and what is below is like what is above, to accomplish the miracle of the One Thing."

— The Emerald Tablet of Hermes Trismegistus

The Correspondence of Levels

Consider the levels at which DMT operates:

• Molecular: A small molecule binds to receptors, triggering intracellular cascades that alter gene expression and protein synthesis.
• Cellular: Neurons grow new dendrites, form new synapses, restructure their connections.
• Network: Brain-wide connectivity patterns reorganize; the default mode network's grip on consciousness loosens.
• Experiential: The boundary between self and world dissolves; ordinary identity evaporates into something vast and undifferentiated.
• Behavioral: Weeks later, patterns that have persisted for years — addictions, depressions, compulsions — are simply... different.

The same intervention produces corresponding effects at every level of description. Change the molecule, change the cell, change the network, change the experience, change the life. As above, so below.

The Hard Problem, Inverted

Philosophy of mind struggles with the "hard problem of consciousness": how does subjective experience arise from physical processes? DMT doesn't solve this problem, but it inverts it in an illuminating way.

Normally, we try to explain consciousness in terms of the brain. DMT shows us the opposite: a change in consciousness that then produces measurable changes in the brain. The experience of ego dissolution — which is purely subjective, accessible only from the first-person perspective — causes structural changes in neural tissue that can be measured with MRI.

This doesn't prove that consciousness is primary or that materialism is wrong. But it does suggest that the relationship between mind and brain is more bidirectional than reductive materialism typically allows. The inner and the outer are not separate domains, but aspects of a single process.

XI. Future Implications

The 68% abstinence rate in the Johns Hopkins/UC Davis trial is a data point, not a conclusion. Much remains to be understood:

• Mechanism refinement: Which specific aspects of the experience produce therapeutic benefit? Is complete ego dissolution necessary, or might lower doses produce similar effects? What's the optimal set and setting?
• Durability: How long do the structural brain changes last? Do some patients relapse after longer follow-up periods? Are "booster" sessions beneficial?
• Generalizability: The trial focused on specific substance use disorders. Will similar results extend to other conditions — depression, PTSD, OCD, eating disorders?
• Integration: Most psychedelic therapy protocols include preparation and integration sessions. How important are these components? Can the effects be enhanced by specific therapeutic frameworks?
• Individual differences: Why do some patients respond dramatically while others don't? Can we predict who will benefit?

The Broader Horizon

Beyond addiction, DMT research points toward a deeper reconceptualization of mental health treatment. The dominant paradigm — daily medication that manages symptoms without addressing underlying architecture — may be supplemented or partially replaced by intensive interventions that produce lasting structural change.

This is not a rejection of conventional psychiatry. SSRIs and other medications help millions of people. But for conditions characterized by "stuck" patterns — where the brain has crystallized into pathological configurations — plasticity-promoting compounds like DMT may offer something qualitatively different: not symptom management, but genuine rewiring.

The Responsibility

None of this should be taken as encouragement for unsupervised experimentation. DMT is not a recreational substance. The experiences it produces can be terrifying as well as transcendent. Set and setting matter enormously. Psychiatric contraindications exist. The legal risks remain substantial in most jurisdictions.

What the research does suggest is that these compounds, in appropriate contexts, represent a genuine therapeutic tool — one that works through mechanisms unavailable to any other class of intervention. The task now is to develop the frameworks — clinical, legal, ethical — that allow this tool to be used safely and effectively.

That work is underway. Oregon and Colorado are building regulatory infrastructure. Johns Hopkins, NYU, Imperial College, and other institutions are running trials. A generation of therapists is training in psychedelic-assisted approaches.

The revolution is not coming. It's here.